Applications of 3-Amino-2-Butenoic Acid Ethyl Ester in Industrial Manufacturing

3-Amino-2-Butenoic Acid Ethyl Ester serves as a targeted intermediate in several specialized chemical sectors. Below, our technical and regulatory team outlines verified downstream uses with specific compliance standards, detailed usage, actual process steps, and end product information relevant to commercial production environments.

1. Pharmaceutical Intermediates for Antiviral API Synthesis

Within pharmaceutical synthesis pipelines, 3-Amino-2-Butenoic Acid Ethyl Ester acts as a key building block in the construction of nucleoside analogs and non-nucleoside reverse transcriptase inhibitors. Its structure supports conjugation with complex moieties in multi-step syntheses, permitting safe, reproducible integration within cGMP production facilities. Fine chemical engineers introduce this ester during protected amination or amidation steps, enabling precise control over impurity profiles and yield enhancement in the final API route. Strict contamination minimization remains mandatory throughout each process stage to meet finished drug quality standards.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals
• European Pharmacopoeia Monographs (Ph. Eur.)
• Chinese Pharmacopoeia (ChP) for relevant intermediates

Typical usage ratio

• 0.1–5.0 w/w% of total synthesis material input
• Usage scales adjusted according to target API batch size and stepwise intermediate conversion efficiency

Downstream process integration

• Added during protected aminolysis or Michael addition step
• Subjected to N-alkylation or further ester transformation under controlled temperature and catalytic conditions
• Purification by column chromatography or crystallization, followed by onward coupling chemistry

Final product types

• Nucleoside antiviral bulk APIs
• HIV non-nucleoside reverse transcriptase inhibitor intermediates
• Active pharmaceutical ingredients for clinical and commercial use
• Rare disease small molecule compounds

2. Agrochemical Intermediate for Selective Herbicide Synthesis

Chemical producers apply 3-Amino-2-Butenoic Acid Ethyl Ester as an essential intermediate in the multistep formation of pyridine and triazine herbicides. This molecule supports the creation of active moieties in selective weed suppression formulations. Technical operators dose it into condensation or cyclization reactions, targeting efficient matrix rearrangement and minimization of side products. Quality verification tests at each stage verify absence of unacceptable residuals and byproducts per regulated tolerances, securing reliable field application and import/export eligibility.

Industry compliance standards

• FAO/WHO Specifications for Plant Protection Products
• REACH Regulation (EC) No 1907/2006 for chemical intermediates
• US EPA FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act)
• ISO 9001:2015 Quality Management Systems for agrochemical manufacturers

Typical usage ratio

• 1.0–10.0 mol% relative to target heterocycle precursor
• Adjusted according to stoichiometry in ring-formation step

Downstream process integration

• Reacts in batch or continuous reactors for heterocycle assembly
• Entry prior to chlorination, amidation, or esterification processes
• Integrated into in-process quality assurance sampling cycle

Final product types

• Pyridine-based herbicide actives
• Triazine herbicide synthesis intermediates
• Technical-grade concentrated herbicide bulk products
• Formulated herbicide solutions for field application

3. Manufacturing Intermediate for Peptidomimetic Synthesis

Research and industrial peptide chemistry teams rely on this ester during synthesis of constrained peptide-mimicking molecules and β-amino acid derivatives. Its unsaturated backbone permits incorporation as non-proteinogenic residues for altered conformational properties. Specialists charge the ester into solid-phase or solution-phase peptide synthesis, optimizing chain elongation and side-chain protection strategies. All manufacturing follows traceable batch records, and controls address the ester’s susceptibility to hydrolysis during deprotection or purification cycles.

Industry compliance standards

• GMP guidelines for oligopeptide production (ICH Q7)
• ISO 13485:2016 for peptide-based diagnostic reagents
• US FDA DMF (Drug Master File) submission for peptide intermediates
• Analytical traceability per USP <823> for peptide inputs

Typical usage ratio

• 3–12 mol% of total amino acid equivalents per synthesis cycle
• Ratio modified based on peptide sequence length and backbone incorporation frequency

Downstream process integration

• Inserted during solid-phase peptide synthesis (SPPS) after standard deprotection
• Subjected to ester hydrolysis and N-terminal amination steps prior to cleavage
• Purified via preparative HPLC or membrane dialysis per lot

Final product types

• Peptidomimetic drug candidates
• Research-grade oligopeptides with conformational constraints
• Biological assay peptide controls
• Stabilized therapeutic or diagnostic peptide entities

4. Intermediate for Fine Chemical Synthesis of Specialty Dyes

3-Amino-2-Butenoic Acid Ethyl Ester finds frequent use in the specialty dye sector, particularly for the construction of acyclic chromophores and functional dye intermediates. Manufacturers introduce the compound in early-stage synthesis, employing selective amination and conjugate addition to install electron-donating units vital for required optical properties. Controlled addition and staged reactivity ensure compliance with regulatory colorant safety and waste effluent limits, while finished batches undergo extensive performance testing per application niche standards.

Industry compliance standards

• REACH Annex XVII for colorant restrictions
• OEKO-TEX Standard 100 for textile dyes
• Restriction of Hazardous Substances (RoHS) Directive for electronic dye applications
• ISO 9001 and ISO 14001 for quality and environmental management systems

Typical usage ratio

• 0.5–3.0 mol% of total dye formulation input
• Ratio specified based on chromophore backbone and desired spectral profile

Downstream process integration

• Charged during stepwise construction of acyclic or aromatic dye structures
• Follows stage of diazotization or oxidative coupling in the overall synthesis scheme
• Undergoes high-purity isolation and batch certification

Final product types

• Textile fiber-reactive dyes
• Fluorescent marker dyes for scientific or industrial use
• Colorant intermediates for plastics and polymers
• Reactive dyes for electronic displays or specialty coatings